Phytopharm goes into free-fall, as Cogane fails in key Parkinson's trial
UK drug developer Phytopharm (LSE: PYM) saw its shares plummet 80% to 2 pence (on February 18), after the company announced disappointing results of the Phase II, randomized, double blind, placebo controlled, dose-ranging trial of Cogane (PYM 50028) in unmedicated patients with early-stage Parkinson’s disease (CONFIDENT-PD).
Analysis of the headline results indicated that Cogane had no beneficial effects on patients’ symptoms measured by the primary or secondary endpoints in the study. The full results of the study will be published in an appropriate scientific forum in due course.
Phytopharm said a review of strategic options for the company will be initiated by the board and shareholders will be kept informed of progress, noting: “No further R&D expenditure will be committed whilst this review is taking place.”
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze